Truist Securities Sees 10-15% Downside in Biogen (BIIB) and 33-70% Upside
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $270.00 price target on Biogen (NASDAQ: BIIB), saying they see10-15 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
